Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
128 results about "Estrogen receptor beta" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Estrogen receptor beta (ER-β), also known as NR3A2 (nuclear receptor subfamily 3, group A, member 2), is one of two main types of estrogen receptor, a nuclear receptor which is activated by the sex hormone estrogen. In humans, ER-β is encoded by the ESR2 gene.
Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
![Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors](https://images-eureka.patsnap.com/patent_img/f250b60a-44c8-42bc-80f9-9cb841814e02/US07074779-20060711-C00001.png "Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors")
![Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors](https://images-eureka.patsnap.com/patent_img/f250b60a-44c8-42bc-80f9-9cb841814e02/US07074779-20060711-C00002.png "Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors")
![Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors](https://images-eureka.patsnap.com/patent_img/f250b60a-44c8-42bc-80f9-9cb841814e02/US07074779-20060711-C00003.png "Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors")
Owner:ORTHO MCNEIL PHARM INC
Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
Owner:ORTHO MCNEIL PHARM INC
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK SHARP & DOHME CORP
Anti aromatase compounds pharmaceutical compositions and uses thereof
Compounds of Formula (I) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating estrogen receptor activity in a cell or patient or treating an estrogen receptor-mediated disorder, particularly breast and other cancers, in a patient in need thereof by administering an effective amount of compound of the invention thereto.
Owner:BOEHRINGER INGELHEIM PHARMA INC
Compounds and methods for treating estrogen receptor-related diseases
The invention provides, in certain embodiments, compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and / or treating diseases related to estrogen receptor alpha 36, for preventing and / or treating respiratory diseases such as asthma, for inducing cell death and / or inhibiting cell proliferation and for preventing and / or treating diseases involving abnormal cell proliferation such as cancers.
Owner:BEIJING SHENOGEN PHARMA GRP
Benzothiophene derivatives as estrogen receptor inhibitors
ActiveUS20160368911A1Organic active ingredientsDipeptide ingredientsEstrogen receptor activityBenzothiophene
A compound of formula (I):or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor,
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.
Owner:BIONOVO
Compounds and compositions as selective estrogen receptor degraders
ActiveUS20140235660A1Decreases CMCAvoid fusesBiocideOrganic chemistryEstrogen receptor activityEstrogen
The present invention relates to compounds of formula I:in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
Owner:NOVARTIS AG
Substituted benzopyrans as selective estrogen receptor-beta agonists
The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer or BPH.
Owner:ELI LILLY & CO
Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions
Compositions derived from Rheum palmatum are provided. Also provided are methods of using said extracts to induce apoptosis in specific cells, especially in a human. Provided as well are uses of the extracts of Rheum palmatum for the preparation of a medicament for the selective induction of apoptosis
Owner:BIONOVO
Liquiritigenin and derivatives as selective estrogen receptor beta agonists
The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.
Owner:BIONOVO
Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
InactiveUS20090258942A1Reduce riskReduced likelihoodBiocideNervous disorderDiseaseEstrogenic Effects
Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Estrogen receptor modulators
InactiveUS6387920B2Unexpected and surprising activity in modulating estrogen receptor activityBiocideNervous disorderDiseaseEstrogen receptor activity
Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.
Owner:CHIRON CORP
Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases
InactiveUS20090312274A1Abolished repressionReduce activationBiocideNervous disorderDiseaseEstrogenic Effects
Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK & CO INC
Selective estrogen receptor-beta ligands
Owner:ASTRAZENECA AB
Estrogen receptor beta variants and methods of detection thereof
The present invention is based on sequencing genomic DNA from human chromosome 6 and cDNAs to define the genomic structure of estrogen receptor beta genes and novel polymorphism in the estrogen receptor gene / protein. Such polymorphism can lead to a variety of disorders that are mediated / modulated by a variant estrogen receptor, such as a susceptibility to cancer, osteoporosis, cardiovascular disorder, etc. Based on this sequencing approach, the present invention provides genomic nucleotide sequences, CDNA sequences, amino acid sequences and sequence polymorphism in the ESR-beta genes, methods of detecting these sequences / polymorphism in a sample, methods of determining a risk of having or developing a disorder mediated by a variant estrogen receptor and methods of screening for compounds used to treat disorders mediated by a variant estrogen receptor.
Owner:APPL BIOSYSTEMS INC
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
Owner:ARVINAS OPERATIONS INC
Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
InactiveUS20100158894A1Effective preventionEffective treatmentOrganic active ingredientsMicrobiological testing/measurementPR - Progesterone receptorReceptor for activated C kinase 1
The present invention provides (1) an agent for the prevention or treatment of an estrogen receptor-negative and HER2-negative breast cancer comprising an Akt inhibitor, (2) an agent for the prevention or treatment of an estrogen receptor-negative, progesterone receptor-negative and HER2-negative breast cancer comprising an Akt inhibitor, (3) a method of screening an agent for the prevention or treatment of a breast cancer which is negative for hormone receptors such as an estrogen receptor, a progesterone receptor, etc. and is negative for HER2, which comprises using an Akt inhibitory activity as an indicator; and so on.
Owner:TOKAI UNIV +1
Substituted benzopyrans as selective estrogen receptor-beta agonists
The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer or BPH.
Owner:ELI LILLY & CO
Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases
InactiveUS20120282222A9Lower Level RequirementsDecreasing VLA-4 expressionBiocideNervous disorderBeta interferonsInterferon beta
This invention relates generally to novel treatments to prevent neurodegeneration in the central nervous system comprising a therapeutic dosage of an estrogen receptor ligand and / or an immunotherapeutic compound, such as beta-interferon, to ameliorate the effects of the neurodegenerative disease and to stimulate repair.
Owner:RGT UNIV OF CALIFORNIA
3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
Substituted benzoxazine and 3,4-dihydrobenzoxazine derivatives possessing activity as estrogen receptor beta (ERβ) modulators are provided which have the structure of formula I wherein the substitutents are as described herein.In addition, a method is provided for preventing, inhibiting or treating the progression or onset of pathological conditions associated with the estrogen receptor and to pharmaceutical compositions containing such compounds.
Owner:BRISTOL MYERS SQUIBB CO
Isoquinolinone derivatives, and preparation method and medical purpose thereof
The invention relates to the fields of pharmaceutical chemistry and organic chemistry, in particular to isoquinolinone derivatives. The compounds can be used for treating various medical indications associated with postmenopausal symptoms, uterine fiber lesions and arterial smooth muscle cell proliferation, particularly ER-(+) breast cancer by inhibiting alpha-estrogen receptor subtype (ER alpha) and through vascular endothelial growth factor receptor (VEGFR-2) bi-target. Meanwhile, the compounds have an obvious inhibiting effect on tumor metastasis, and have a general formula I.
Owner:CHINA PHARM UNIV
Selective estrogen receptor-beta ligands
The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-β ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.
Owner:ASTRAZENECA AB
Benzothiophene derivatives as estrogen receptor inhibitors
A compound of formula (I):or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Estrogen receptor ligand treatment for neurodegenerative diseases
InactiveUS20120328566A9Decrease ameliorate clinical symptomReduce dosageNervous disorderPeptide/protein ingredientsAnti-inflammatory analgesicsEndocrinology
The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand in combination with a standard, anti-inflammatory agent.
Owner:RGT UNIV OF CALIFORNIA
Substituted benzopyrans as selective estrogen receptor-beta agonists
The present invention relates to novel benzopyran ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis. Formula (I), wherein G is —O—, —S(O)n, —CF2—, —C(O)—, —CR1H— or —CR2(OH)—; R is halo, (C1-C4)alkyl or R3—(CH2)m—; R1 is F, hydroxyl, cyano, trifluoromethyl, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkylcarbonyloxy or benzyl; R2 is trifluoromethyl or (C1-C4)alkyl; R3 is cyano, hydroxyl, (C2-C4)alkenyl, (C1-C4)alkoxy or (C1-C4)alkoxycarbonyl; n is 0, 1 or 2; and m is 0, 1 or 2; and pharmaceutically acceptable salts thereof.
Owner:ELI LILLY & CO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com